dm+d
Unassigned
New Medicines
Primary biliary cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA)
Information
New molecular entity
Ipsen
Ipsen
Development and Regulatory status
Phase II Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes
Category
Dual peroxisome proliferator-activated alpha and delta receptor agonist (PPARα/δ agonist)
Autoimmune disease of biliary system; prevalence estimated as 12.9 per 100,000 population in the UK with up to 90% of cases occurring in women [2].
Primary biliary cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA)
Oral